GlobeNewswire by notified

Transactions in connection with share buy-back program

Share

Announcement

A.P. Møller - Mærsk A/S – Transactions in connection with share buy-back program

On 5 May 2021, A.P. Møller - Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 32bn (around USD 5bn) to be executed over a period of two years. On 12 August 2022 the Company announced an increase in the current share buy-back program from DKK 32bn (around USD 5bn) to DKK 39.3bn (around USD 6bn).

As announced on 3 November 2022, during the third phase of the program running from 3 November 2022 up to 3 May 2023, the Company will buy back A and B shares for an amount of up to DKK 11bn. The third phase of the share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”).

The following transactions have been made under the program in the period Monday December 19, 2022 to Friday December 23, 2022:

Number of A sharesAverage purchase price A shares, DKKTransaction value,
A shares, DKK
Accumulated, last announcement (market and A.P. Møller Holding A/S)219,1433,806,989,385
19 December 202276114,628.357411,132,180
20 December 202277414,624.082711,319,040
21 December 202278615,045.712511,825,930
22 December 202278515,332.828012,036,270
23 December 202279315,599.949612,370,760
Total 19-23 December Friday3,89958,684,180
Bought from A.P. Møller Holding A/S*4,13415,051.041462,221,005
Accumulated in third phase of the program (market and A. P. Møller Holding A/S)40,288593,139,687
Accumulated under the program (market and A. P. Møller Holding A/S)227,1763,927,894,570
Number of B sharesAverage purchase price B shares, DKKTransaction value,
B shares, DKK
Accumulated, last announcement (market, A.P. Møller Holding A/S and the Foundation)962,66617,594,317,558
19 December 20223,01614,852.617744,795,495
20 December 20223,10814,853.716246,165,350
21 December 20223,13215,281.475147,861,580
22 December 20223,18815,562.903149,614,535
23 December 20223,15215,844.362349,941,430
Total 19-23 December Friday15,596238,378,390
Bought from A.P. Møller Holding A/S*12,50115,284.5900191,072,660
Bought from the Foundation*3,93915,284.528660,205,758
Accumulated in third phase of the program (market, A. P. Møller Holding A/S and the Foundation)160,7262,420,016,349
Accumulated under the program (market, A. P. Møller Holding A/S and the Foundation)994,70218,083,974,366

*) According to separate agreements, A.P. Møller Holding A/S and A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.

Page 1 of 2

With the transactions stated above, the Company owns a total of 195,344 A shares and 862,852 B shares as treasury shares, corresponding to 5.66% of the share capital.

Details of each transaction are included as appendix.

Copenhagen, 27 December 2022

Contact persons:

Head of Investor Relations, Sarah Spray, tel. +45 3147 4170
Head of Media Relations, Jesper Løv, tel. +45 6114 1521

Page 2 of 2

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

GXO Reports First Quarter 2024 Results7.5.2024 22:30:00 CEST | Press release

First quarter revenue of $2.5 billion, up 6% year over year; organic revenue growth1 of 1%Signed new business wins of approximately $250 million in annualized revenue in 1Q 2024; up 55% year over yearSales pipeline at 12-month high of $2.2 billionCompleted acquisition of Wincanton on April 29, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO) today announced results for the first quarter 2024. Malcolm Wilson, chief executive officer of GXO, said, “We delivered a strong start to 2024, reflecting our solid execution amid improving industry dynamics. The company grew revenue by 6% to $2.5 billion and delivered positive organic revenue growth, while gaining market share. We look forward to driving continued growth throughout 2024 and are on track to achieve our full-year outlook. “We’re seeing strengthening demand from global blue-chip customers to realize operational efficiencies today while planning fulfillment strategies to meet their future needs.

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update7.5.2024 22:30:00 CEST | Press release

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent Business Developments Clinical and Regulatory Update Enrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by

SFL - Invitation to Presentation of Q1 2024 Results7.5.2024 22:19:00 CEST | Press release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following: A: Join Conference CallWebcast In Listen Only Mode: Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast", or access directly via the webcast link below. The webcast with slideshow will be played live from this platform: SFL Corporation Ltd. Q1 2024 Webcast B: Join Conference Call AndParticipate in Live Q&AthroughZoom: Join through the Zoom link below to ask a question: SFL Q1 2024 Q&A Meeti

Oculis Publishes Invitation to the Annual General Meeting7.5.2024 22:05:00 CEST | Press release

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior

Nokia Corporation: Repurchase of own shares on 07.05.20247.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 07 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 07.05.2024 Espoo, Finland – On 07 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL376,2023.48CEUX--BATE--AQEU--TQEX--Total376,2023.48 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye